Vesugen

Also known as: Lys-Glu-Asp

Not FDA-approved

Last verified: October 30, 2026

At a glance

FDA approval Not FDA-approved No record in Drugs@FDA

Randomized controlled trials 0 of 32 publications on PubMed

Registered clinical trials 0 0 active

Adverse event reports 0 0 classified as serious

Vesugen is not an FDA-approved drug: Drugs@FDA has no record of it.
PubMed lists 32 publications mentioning it, including 0 randomized controlled trials and 11 animal-only studies.
No study registered on ClinicalTrials.gov tests it as an intervention.
FDA’s adverse event system (FAERS) has no reports mentioning it.

Research topics

Aging 9
Cellular Senescence 7
Cell Differentiation 6
Cell Proliferation 6
Dipeptides 5
Epigenesis, Genetic 4
Fibroblasts 4
Neurons 4
Alzheimer Disease 3
Apoptosis 3

Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).

Regulatory status

Drugs@FDA applications

No application found in Drugs@FDA, FDA's database of approved drugs.

Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query

FDA compounding safety list

Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.

Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026

Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.

Scientific publications

All publications 32
Human (MeSH) 17
Animal only 11
Clinical trials 0
Randomized controlled trials 0
Systematic reviews & meta-analyses 0
Case reports 0
Retracted 0

Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.

Latest publications

[Peptidergic regulation of age-related alterations in the cardiovascular system.]. Review 2026 Advances in gerontology = Uspekhi gerontologii
The Influence of Short Peptides on Cell Senescence and Neuronal Differentiation. Unclassified 2025 Current issues in molecular biology
Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes. Human study 2024 International journal of molecular sciences
[Prospects for use of short peptides in pharmacotherapeutic correction of Alzheimer's disease.]. Review 2024 Advances in gerontology = Uspekhi gerontologii
Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation. Review 2022 Cells
Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease. Review 2021 Bulletin of experimental biology and medicine
Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer's Disease. Unclassified 2021 Pharmaceuticals (Basel, Switzerland)
[Epigenetic regulation of adaptogenesis by pathology and aging.]. Human study 2021 Advances in gerontology = Uspekhi gerontologii
Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides. Human study 2020 Molecular biology reports
[Short peptides: regulation of skin function during aging.]. Human study 2020 Advances in gerontology = Uspekhi gerontologii

Source: PubMed (NCBI) · verified October 30, 2026

Clinical trials

No registered study on ClinicalTrials.gov lists this peptide as an intervention.

Source: ClinicalTrials.gov · verified October 30, 2026

Adverse event reports

No FAERS reports mention this peptide.

Source: FDA FAERS · verified October 30, 2026 · API query

Change history

No changes since monitoring began on October 30, 2026.